Clinical trial NCT02293408: Natural History Study to Characterise the Course of Disease Progression in Participants With Mucopolysaccharidosis Type IIIB
Official title: A Prospective Cross-Sectional and Longitudinal Study With Additional Retrospective Chart Review to Evaluate Clinical and Biochemical Characteristics and Disease Progression in Patients With Mucopolysaccharidosis Type IIIB
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: MPS IIIB (Sanfilippo B Syndrome)
Keywords: MPS IIIB
Mucopolysaccharidosis
Mucopolysaccharidosis type IIIB
Sanfilippo Syndrome Type B
Lead sponsor: Alexion Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2014-11-18
Enrollment: 30
Sex: ALL
Minimum age (years): 1
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 27 participants with MPS IIIB were enrolled and analyzed in Component 1.

Component 1 (27 participants): The participant has a definitive diagnosis of MPS IIIB. Component 2 (15 participants from Component 1): The participant is considered to be at risk of rapid disease progression.

Brief summary: The objectives of this study are to describe the clinical and biochemical characteristics and course of disease progression in participants with Mucopolysaccharidosis type IIIB (MPS IIIB)


Eligibility criteria: Inclusion Criteria:

A participant must meet all of the following inclusion criteria to be eligible for this study:

1. The participant has a definitive diagnosis of MPS IIIB, as determined by either of the following:

   1. Documented deficiency in alpha-N-acetyl-glucosaminidase (NAGLU) enzyme activity or
   2. Documented functionally-relevant mutations in both alleles of the NAGLU gene.
2. The participant is at least 1 year of age (biological age).
3. The participant or the participant's parent provides informed consent.
4. The participant is willing and able to comply with protocol requirements to the extent that may be expected of a participant with cognitive impairment.

In addition to the eligibility criteria above, a participant must meet all of the following criteria for Component 2:

1. The participant meets criterion a or criterion b below.

   a. The participant is considered to be at risk of rapid disease progression based on at least 1 of the following criteria:

   i. The participant has documented mutations of the NAGLU gene that are reported to be linked to rapid disease progression (for example, disease onset before 6 years of age), or

   ii. The participant has a sibling, or other first- or second-degree relative with rapidly progressing MPS IIIB (for example, disease onset before 6 years of age).

   b. The participant had disease onset prior to 6 years of age (biological age), as defined by:

   i. Cognitive delay evaluated by Bayley Scales of Infant Development, Third Edition (BSID-III) or Kaufman Assessment Battery for Children, Second Edition (KABC-II), or

   ii. Language delay, plateauing, or regression of language skills as determined by the Investigator (for example, participant uses isolated words, associated words such as 2-word combinations, sentences, poor or reduced language, and/or difficult to understand).
2. The participant has an age equivalent of ≥1 year on the Vineland Adaptive Behavior Scales, Second Edition (Vineland II).

Exclusion Criteria:

A participant who meets any of the following exclusion criteria will be ineligible for this study:

1. The participant has visual or hearing impairments sufficient to preclude cooperation with neurodevelopmental testing.
2. The participant has a history of poorly-controlled seizure disorder.
3. The participant is currently receiving medication, which, in the Investigator's opinion, would be likely to substantially confound interpretation of the results (for example, the participant has been on the current dose of psychotropic medication for less than 3 months).
4. The participant is receiving a newly increased dose of melatonin (for example, less than 3 months on current dose).
5. The participant has previously received an investigational therapy for MPS IIIB (with the exception of high dose Genistein \>150 milligram/kilogram (mg/kg)/day, which will require a minimum of 3 months wash-out before entering the study) or has had hematopoietic stem cell transplant (HSCT).
6. The participant has any other prior or ongoing medical condition that may present a safety risk, interfere with study compliance, or confound data interpretation.

Primary outcomes:
measure: Collection And Analysis Of Clinical Characteristics Of MPS IIIB
timeFrame: Baseline to Week 43
measure: Longitudinal Analysis Of The Course Of Disease Progression In Participants With MPS IIIB
timeFrame: Baseline to Week 43
Secondary outcomes:
Other outcomes:
Locations:
city: Minneapolis
country: United States
state: Minnesota
city: Pittsburgh
country: United States
state: Pennsylvania
city: Porto Alegre
country: Brazil
city: Monza
country: Italy
city: Coimbra
country: Portugal
city: Barcelona
country: Spain
city: Birmingham
country: United Kingdom
Study officials:
References: